ArticleDrug design, development and therapy2025
Anti-Inflammatory Modified Fuzi Decoction Antagonizes Synovial TNF-α/TRAF2/NF-κB Signaling to Remedy Osteoarthritis.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pharmacological, Toxicological, Phytochemical and Ethnobotanical Insights into North AmericanMolecules (Basel, Switzerland) · 2026Review
- The Interplay between Osteoarthritis and the Microbiome-joint Axis: A Systemic Perspective on Novel Therapeutic Targets.Current rheumatology reviews · 2026Article
- NF-κB signaling in osteoarthritis: integrating mechanical stress, innate immunity, and cartilage degeneration.Frontiers in immunology · 2026Review
- Oleanolic acid cubic liquid crystal nanoparticle-based thermosensitive gel attenuates knee osteoarthritis symptoms in rats.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the pharmacodynamic effects and therapeutic mechanisms of modified Fuzi decoction (MFZD) in osteoarthritis (OA), particularly OA-related inflammation. Methods: The main components of MFZD were identified using Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS). An OA model was established in Sprague-Dawley rats via intra-articular injection of monoiodoacetate (MIA) to evaluate the anti-OA efficacy of MFZD via gavage. In vivo studies, including pain behavior evaluation, histopathological observation, immunohistochemical analysis, enzyme-linked immunosorbent assay (ELISA), Meso Scale Discovery (MSD), and Western blot (WB), were carried out to demonstrate the anti-inflammatory and anti-degenerative potency of MFZD against OA. Potential targets and pathways of MFZD were identified via network pharmacology analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, respectively. Subsequently, the tumor necrosis factor (TNF) signaling and related targets were validated in vitro by WB. For in vitro validations, primary synovial fibroblasts were isolated from rats and treated with MFZD-containing serum (MFCS) in the presence of TNF-α. Results: UPLC-MS/MS analysis identified key compounds in MFZD, including trans-cinnamaldehyde, atractylenolide I, lobetyolin, paeoniflorin, pachymic acid, carmichaeline, talatisamine, fuziline, benzoylhypacoinine, benzoylmesaconine, benzoylaconine, hypaconitine, deoxyaconitine, mesaconitine, and aconitine. MFZD treatment improved the paw withdrawal threshold (PWT), alleviated histopathological damage, reduced TNF-α and monocyte chemotactic protein-1 (MCP-1) in the serum, and remedied the abnormal anabolism/catabolism of cartilage. TNF signaling was identified through network pharmacology analysis as the anti-inflammatory mechanism of MFZD, and validated by WB results showing that MFCS treatment reduced TNF-α-induced protein expression of p-MKK3/MKK6, p-p38, TRAF2, p-p65, and VCAM1. Conclusion: This study demonstrated that MFZD exerts anti-degenerative and anti-inflammatory potency against OA and revealed the TNF-α/TRAF2/NF-κB signaling related anti-inflammatory mechanism of MFZD for the first time, offering mechanistic insights into its potential in OA therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.